Details of the Drug

General Information of Drug (ID: DMXC1K9)

Drug Name

Alpha 1-PI

Synonyms

Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

Indication

Disease Entry	ICD 11	Status	REF
Alpha-1 antitrypsin deficiency	5C5A	Approved	[1]
Cancer related pain	MG30	Withdrawn from market	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

325.4

Logarithm of the Partition Coefficient (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 64.57 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.32 hours [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 18.99 L/kg [3]

Chemical Identifiers

Formula: C21H27NO2
IUPAC Name: 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
Canonical SMILES: CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
InChI: InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
InChIKey: UYNVMODNBIQBMV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3689
ChEBI ID: CHEBI:93829
CAS Number: 23210-56-2
DrugBank ID: DB08954
TTD ID: D0I0DL

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor ionotropic NMDA 2B (NMDAR2B)	TTN9D8E	NMDE2_HUMAN	Antagonist	[4]
Pancreatic elastase 1 (CELA1)	TT3NKIB	CELA1_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5472).
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
5	Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
6	sigma(2)-receptor ligand-mediated inhibition of inwardly rectifying K(+) channels in the heart. J Pharmacol Exp Ther. 2007 Jul;322(1):341-50. doi: 10.1124/jpet.107.122044. Epub 2007 Apr 25.